ImmunoGenesis Announces Positive Preclinical Glioblastoma and Pancreatic Cancer Data for STimulator of INterferon Genes (STING) Agonist Published in Two Scientific Journals
STING agonist can induce innate immune responses that allow the immune system to fight otherwise immunologically resistant cancers
Phase 1 canine glioblastoma veterinary trial data show the promise of STING agonist as potential future therapy for human glioblastoma
Data support the advancement of ImmunoGenesis’ STING-Immune Stimulating Antibody Conjugate (ISAC) in immunologically cold tumors